All articles tagged with #neuroprotection
Nature Metabolism reports that irisin, a myokine released during exercise, promotes neuronal survival in an inflammation-driven model of multiple sclerosis, suggesting a possible mechanism by which physical activity could modify disease progression.
A mouse study suggests the bodybuilding supplement HMB may slow Alzheimer’s-related changes by reducing amyloid plaques and neurofibrillary tangles and boosting neurotrophic factors, potentially supporting memory, but findings are preliminary and not yet proven in humans.
Researchers tested IKVAV-PA, a peptide-based nanomaterial, in a mouse model of acute ischemic stroke and found that systemic delivery allows the molecules to cross the blood-brain barrier and reduce brain tissue damage, inflammation, and harmful immune responses after reperfusion, indicating potential as an adjunct therapy—though human safety and long-term efficacy remain to be studied.
A new study shows that the drug candidate P7C3-A20 can restore cognitive functions, reduce brain damage, and repair the blood-brain barrier in mice with advanced Alzheimer's, suggesting potential for future human treatments by restoring NAD+ levels, though more research is needed.
A small Brazilian study found that microdoses of cannabis extract may help stabilize cognitive decline in patients with mild Alzheimer's disease, showing potential for a new therapeutic approach without psychoactive effects. Further research with larger samples is needed to confirm these findings.
A study suggests that doxycycline, an antibiotic used for acne, may be linked to a 30% lower risk of developing schizophrenia in adolescents, possibly due to its effects on immune response and inflammation, though further research is needed to confirm causality.
A new study suggests that specific immune cells in the brain called microglia can switch to a protective state that may prevent or slow Alzheimer's disease progression, opening potential avenues for immunotherapy. The research highlights the importance of microglia's plasticity and their role in combating harmful protein buildup associated with Alzheimer's, with implications for future treatments targeting immune cell states.
The study investigates how lymphoid gene expression supports neuroprotective functions of microglia in the human brain, particularly in the context of Alzheimer's disease, using post-mortem samples, induced pluripotent stem cells, and mouse models to explore microglial roles and gene regulation.
Researchers have identified two compounds, K102 and K110, capable of repairing the myelin sheath damaged by multiple sclerosis, showing promise for reversing nerve injury and advancing toward human clinical trials.
Scientists discovered that disrupting the toxic NMDAR/TRPM4 protein complex with the molecule FP802 in mice can slow Alzheimer's progression, preserve cognitive functions, and reduce amyloid buildup, offering a promising new therapeutic approach for neurodegenerative diseases.
Emerging research highlights the importance of the full vitamin B complex, including B1, B2, B3, B5, B7, and B9, in supporting brain energy, neurotransmitter synthesis, and potentially slowing cognitive decline. Incorporating B-rich foods like whole grains, leafy greens, nuts, and eggs into your diet can help maintain brain health without supplements, but always consult a healthcare professional before making dietary changes.
A new study suggests that low levels of lithium in the brain are linked to Alzheimer's disease, with findings indicating that lithium naturally occurs in the brain and plays a crucial role in its function. Reduced lithium levels may serve as an early warning sign and a potential target for treatment, as supplementing lithium in animal models reversed brain damage and improved memory, highlighting a promising new approach for Alzheimer's prevention and therapy.
A large-scale U.S. government-funded study suggests that marijuana use may be linked to enhanced cognitive abilities and brain health in older adults, potentially slowing neural aging processes and preserving cognitive function, though more research is needed to understand the mechanisms involved.
A recent study suggests that GLP-1 agonists may offer better protection against dementia in people with type 2 diabetes compared to metformin, with findings indicating a significantly lower risk of developing dementia and Alzheimer’s disease among GLP-1 users. The research highlights the potential neuroprotective benefits of GLP-1 medications, which could influence future treatment strategies for diabetes and cognitive decline.
Recent studies presented at SNIS suggest that GLP-1 receptor agonists like Ozempic, commonly used for diabetes and obesity, may have neuroprotective effects, including reducing stroke risk and improving survival and recovery outcomes after stroke and brain hemorrhages.